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1. Introduction 
Functional RNAs, e.g., aptamers (Lee et al., 2005; Que-Gewirth & Sullenger, 2007), ribozymes 
(Malhbacher et al., 2010), antisense oligonucleotides (Hnik et al., 2009), and double-stranded 
RNA (dsRNA) (Watts & Corey, 2010), hold promise for use as RNA drugs in the near future. 
However, the linear form of RNA without chemical modifications is rapidly degraded in both 
human serum and cell extracts due to endogenous nucleases. Therefore, it will likely be 
necessary to chemically modify these RNA drugs (Pestourie et al., 2005; Watts et al., 2008) to 
protect them from nuclease-dependent degradation. In fact, the recently developed aptamer 
drug pegaptanib sodium (Macugen®; Pfizer) for use against macular degradation consists of 
2'-F- or 2'-OCH3-substituted nucleotides, thus preventing its rapid degradation in the ocular 
environment. Although at present it is the only commercially available RNA drug, we infer 
from the selling price of Macugen® that similar novel chemically modified RNA drugs are 
likely to be expensive because production of a chemically modified RNA molecule and scaling 
up the production yield of the RNA are expensive in principle. Therefore, the development of 
not only inexpensive but also durable RNA drugs will facilitate the widespread use of easily 
administered RNA drugs. To address the problems outlined above, our research group has 
considered in vivo circular RNA expression as a model for inexpensive RNA drug production 
because circular RNA molecules are resistant to exoribonucleases without any chemical 
modifications under cellular conditions. Therefore, the circular form of RNA would be a 
promising RNA drug candidate without requiring chemical modification. 
Circular RNA can be produced both in vitro and in vivo using two methodologies. The first 
makes use of ligase to ligate both ends of the linear form of RNA transcripts (Chen & Sarnow, 
1998; Beaudry & Perreault, 1995), while the second uses a spontaneous group I intron self-
splicing system, designated as the permuted intron-exon (PIE) method (Puttaraju & Been, 
1992). The latter technique is the only methodology available for in vivo circular RNA 
production because it has no requirement for proteinaceous components, such as ligases. 
Therefore, the PIE method is a promising economical methodology for producing circular 
RNA drugs. In this chapter, we describe our circular streptavidin RNA aptamer expression by 
the PIE method as a model for RNA drug production (Umekage & Kikuchi, 2006, 2007, 2009a, 
2009b). Then, we discuss our recent improvements in the circular RNA expression technique, 
i.e., the tandem one-way transcription of PIE (TOP) method, to achieve higher yields of in vivo 
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circular RNA expression. In this system, we achieved production of approximately 0.19 mg of 
circular RNA from a 1-L culture of the Escherichia coli strain JM101Tr. To our knowledge, this is 
the highest circular RNA expression yield reported to date. Finally, we will discuss in vivo 
circular RNA expression by the marine phototrophic bacterium Rhodovulum sulfidophilum. This 
bacterium produces RNA both within the cell and in the culture medium in nature and 
produces no RNases in the culture medium (Suzuki et al., 2010), whereas strong RNase activity 
is observed in the culture medium of a conventional E. coli strain that can be used for RNA 
production. Therefore, we speculated that Rdv. sulfidophilum would be a suitable strain for 
RNA production in the culture medium bypassing the total RNA extraction procedure to 
break the cell membrane, such as the acid guanidinium thiocyanate phenol chloroform 
(AGPC) method (Chomczynski & Sacchi, 1987). 
2. Group I intron self-splicing and the permuted intron-exon (PIE) method 
Group I intron self-splicing RNA from the ciliate Tetrahymena was the first discovered 
ribozyme (Cech et al., 1981). The group I intron sequence has been widely detected in 
eukaryotes (Cech et al., 1981), prokaryotes (Xu et al., 1990) and some bacteriophages 
(Ehrenman et al., 1986). This self-splicing does not require any proteinaceous components 
but does require the presence of Mg2+ and guanosine nucleotides (Cech et al., 1981). After 
self-splicing, the concomitant ligation of the two exons takes place (Fig. 1). This self-splicing 
mechanism consists of a well-defined two-step transesterification mechanism, and the 
sequential self-splicing steps take place after formation of the higher-order intron 
architecture. In the first step, a guanosine nucleotide attacks the phosphate at the 5' splicing 
site and scission occurs between the upstream exon and the intron, and the guanosine 
nucleotide is then ligated to the 5' side of the intron. Next, the hydroxyl group of the 3' end 
of the upstream exon shows nucleophilic attack of the downstream splicing site of the 
phosphorus, and intron circularisation and exon ligation occur. Therefore, it is assumed that 
both the 5' end of the 5' half exon and 3' end of the 3' half exon are somehow ligated before 
self-splicing occurs, and the resulting spliced exon product has a circular conformation. 
Several biochemical (Galloway-Salbo et al., 1990) and structural investigations of group I 
intron self-splicing (Stahley & Atrobel, 2006) indicated that the peripheral region of the 
intron architecture and internal open reading frame (ORF) sequence does not participate in 
formation of the intron architecture and the self-splicing event mentioned above. Theses 
investigations allowed us to permute the order of the intron and exon sequence without 
distorting the tertiary structure of the permuted intron architecture. Puttaraju & Been (1992) 
first reported that circular permutation of the group I intron from both the Anabena pre-
tRNA intron and the Tetrahymena intron generated a circular RNA exon in vitro. Another PIE 
from the T4 phage group I intron was later shown to be applicable for generating the 
circular exon (Ford & Ares, 1994). As the exon sequence does not participate in the self-
splicing reaction, the exon sequence in the PIE sequence is replaced with another foreign 
sequence. Based on this concept, several circular RNAs have been developed by the PIE 
method, i.e., the tat-activated response (TAR) RNA (Puttaraju & Been, 1995; Bohjanen et al., 
1996; Bohjanen et al., 1997), rev responsive element (Puttaraju & Been, 1995), HDV ribozyme 
(Puttaraju et al., 1993; Puttaraju & Been, 1996), tRNA (Puttaraju & Been, 1992), Bacillus 
subtilis PRNA (Puttaraju & Been; 1996), mRNA encoding GFP (Perriman & Ares, 1998), yeast 
actin exon (Ford & Ares, 1994), hammerhead ribozyme (Ochi et al., 2009), and streptavidin 
RNA aptamer (Umekage & Kikuchi, 2006, 2007, 2009a, 2009b) (Table 1). 
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Fig. 1. Group I intron self-splicing RNA and the permuted intron-exon (PIE). Predicted 
secondary structure of the td group I intron sequence (upper left side) and the PIE sequence 
(upper right side). The pink and black lines show the intron sequence and the green line 
indicates the internal ORF sequence. Coloured horizontal lines shown in the middle of this 
figure illustrate the circular permutation of the td intron. In the normal td intron (left side), 
after transesterification, the exon sequence is ligated. In the permuted td intron (right side), 
the exon sequence is circularised and a split intron sequence appears. Circularisation of the 
exon sequence by the PIE method also requires magnesium ions and guanosine nucleotides.  
These results confirmed the availability of the PIE method to yield a wide variety of 
circular RNAs. As circularisation is driven only by magnesium ions and guanosine 
nucleotides, the circularisation of RNA in E. coli (Puttaraju & Been, 1996; Perriman & Ares, 
1998; Umekage & Kikuchi, 2007, 2009a, 2009b) and Saccharomyces cerevisiae (Ford & Ares, 
1994; Puttaraju & Been, 1996) have been demonstrated, and the in vivo expressed circular 
RNAs reported above are functionary active. Our group also showed that the circular 
streptavidin RNA aptamer produced both in vitro and in E. coli (Umekage & Kikuchi, 
2006, 20007, 2009a, 2009b), and the expressed circular streptavidin RNA aptamer was 
purified from the total RNA fraction by the solid-phase DNA probe method (Suzuki et al., 
2002). This is the first evidence that both in vitro and in vivo circularisation of an RNA 
aptamer and the in vivo circularised RNA generated by the PIE method can be purified 
(Umekage & Kikuchi, 2009a). 
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in vitro Puttaraju & Been, 1992 
HDV ribozyme Anabaena in vitro 
Puttaraju et al., 1993; 
Puttaraju & Been, 1996 
td exon from T4 phage T4 phage 
in vitro & 
E. coli DH5ǂ & 
S. cerevisiae IH1097 
Ford & Ares, 1994 
actin ORF from yeast T4 phage 
in vitro &
E. coli DH5ǂ& 
S. cerevisiae IH1097
Ford & Ares, 1994 
Rev-responsive 
element RNA
Anabaena in vitro Puttaraju & Been, 1995 
tat-activated response 
RNA 
Anabaena in vitro 
Puttaraju & Been, 1995 
Bohjanen et al., 1996; 
Bohjanen et al., 1997 
B. subtilis PRNA Anabaena 
in vitro & 
E. coli BL21(DE3) 
Puttaraju & Been, 1996 
GFP ORF T4 phage 
in vitro & 
E. coli BL21(DE3) 
Perriman & Ares, 1998 
streptavidin aptamer T4 phage 
in vitro &
E. coli JM109(DE3) 
& E. coli JM101Tr 
Umekage & Kikuchi, 
2006, 2007, 2009a, 
2009b 
hammerhead ribozyme T4 phage in vitro Ochi et al., 2009 
streptavidin aptamer T4 phage 
Rdv. sulfidophilum 
DSM 1374T 
this study (see 2.4) 
Table 1. Summary of circular RNA production. “Category of circularised RNA”: Source of 
the circularised exon sequence. “Intron”: Source of the intron sequence used for constructing 
the PIE sequence. “Expression”: Circular RNA production in vitro or in vivo (the expression 
host strain is listed). 
On the other hand, we found that this circularisation affected the original activity of the 
linear form of functional RNAs. The dissociation constant (Kd) of the circular streptavidin 
RNA aptamer increased (Umekage & Kikuchi, 2009a) and ribozyme activity of the 
hammerhead ribozyme decreased (Ochi et al., 2009). These observations suggest that 
structural constraints were induced by circularisation. Although it is also important to take 
into consideration the circular RNA structure before constructing the PIE sequence, it is 
difficult to predict the tertiary structure of the circularised RNA molecule.  
Therefore, optimisation of the circularised sequence would be required involving 
randomising the spacer sequence, inserting the poly(A) sequence, etc. We succeeded in 
recovering the functional activity of the circular hammerhead ribozyme by adding a poly(A) 
spacer between the ribozyme sequence and the indispensable linkage sequence derived 
from the exon sequence for circularisation by the PIE method (Ochi et al., 2009), and the 
recovered ribozyme activity of the circular hammerhead ribozyme was dependent on the 
length of the poly(A) spacer (Ochi et al., 2009).  
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Fig. 2. Schematic representation of the plasmid pGEM-3E5T7t, and the predicted secondary 
structure of the circular streptavidin RNA aptamer produced from the plasmid. (A) The 
figure shows pGEM-3E5T7t. The PIE sequence is located between the T7 promoter sequence 
and the T7 terminator sequence. The PIE sequence consists of the 3' half intron, streptavidin 
aptamer sequence and 5' half intron sequence. The intron sequence is derived from the td 
intron of bacteriophage T4. (B) Predicted secondary structure of the circular streptavidin 
RNA aptamer. Upper and lower case letters indicate the aptamer sequence and exon 
sequence derived from the original exon sequence of the td gene, respectively. Streptavidin 
RNA is derived from the S1 aptamer reported by Srisawat & Engelke (2001). The thick 
arrow represents the self-ligated junction. The thin arrow (anticlockwise) indicates the 
orientation of the circular RNA from 5' to 3'. The thin line and black dot represent Watson–
Crick base pairing and G-U Wobble base pairing, respectively. 
2.1 In vivo circular streptavidin RNA aptamer expression by the PIE method 
To demonstrate in vivo circular RNA expression, our group designed the circular 
streptavidin RNA aptamer as a model RNA dug and the PIE sequence for production of the 
circular streptavidin RNA aptamer. The PIE sequence consists of the 3' half intron, aptamer 
sequence and 5' half intron sequence in this order (Fig. 2A), with omission of the internal 
ORF sequence (Fig. 1, shown as the green-coloured line) in the td intron for this PIE 
construction that does not participate in the self-splicing reaction of the intron. We 
constructed a circular streptavidin RNA aptamer expression vector, pGEM-3E5T7t, which 
consists of three parts: the T7 RNA promoter, the PIE sequence and the T7 terminator 
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sequence in the multicloning site in the standard cloning vector, pGEM-3Z (Promega) (Fig. 
2A). The streptavidin RNA aptamer sequence in the PIE sequence was derived from the S1 
aptamer sequence reported by Srisawat & Engelke (2001), and the intron sequence derived 
from the td intron of bacteriophage T4. Both ends of the resulting circular streptavidin RNA 
aptamer sequence were ligated by an indispensable linker sequence derived from a partial 
exon sequence of the td gene of bacteriophage T4 (Fig. 2b, lower case).  
To express the circular streptavidin RNA aptamer in vivo, pGEM-3E5T7t was transformed 
into JM109(DE3) (endA1 recA1, gyrA96, thi-1, hsdR17 (rK-, mK+), relA1, supE44, (lac-proAB), 
[F', traD36, proAB, lacIqZ, M15], (DE3)) (Promega), which encodes an isopropyl-ǃ-D-
thiogalactopyranoside (IPTG)-inducible T7 RNA polymerase on its genomic sequence. The 
full-growth culture of JM109(DE3) harbouring pGEM-3E5T7t was transferred into 1 L of 
fresh LB broth and cultured until the optical density at 600 nm (OD600) reached 0.7 at 30C. 
Then, IPTG was added to a final concentration of 0.4 mM and circular RNA expression was 
induced by cultivation for 2 h at 30C with vigorous shaking. After extraction of the total 
RNA, which included the circular RNA, using the AGPC method to break the cell 
membrane (Chomczynski & Sacchi, 1987), the circular RNA expression in the total RNA 
fraction was monitored by ethidium bromide staining and Northern blotting analysis. 
We performed two-dimensional (2D) denaturing polyacrylamide gel electrophoresis (2D 
PAGE) (Schumacher, 1983; Feldstein, 2007) to monitor whether the circular RNA was 
present in the recovered total RNA fraction. This 2D-electrophoresis is based on the 
differences in migration behaviour between linear and circular RNA under denaturing gel 
conditions. Unlike linear RNA, migration of a circular RNA molecule of the same length 
varies with the acrylamide and/or bis-acrylamide concentration on denaturing 
polyacrylamide electrophoresis (PAGE). Therefore, after 2D denaturing gel-
electrophoresis, the linear RNA fraction has migrated in the diagonal direction, whereas 
the circular RNA appears beside the diagonal line of the linear molecule. Both ethidium 
bromide staining and Northern blotting analysis showed a single spot beside the diagonal 
migration line, indicating that the circular RNA was present in the total RNA fraction. 
This spot was eluted and subjected to partial alkaline digestion. The partially digested 
nicked circular RNA migrated faster than the intact circular molecule on denaturing 10% 
PAGE, confirming that the eluted RNA was a circular form. The degradation products of 
circular RNA were not detected by Northern blotting analysis. This clearly showed that 
the circular RNA expressed in E. coli cells was protected against exonuclease-induced 
degradation, such as that induced by ribonuclease II (RNase II) (Frazão et al., 2006). The 
expression level of the circular RNA aptamer was determined to be 2.5 ± 0.46 ng per 1 μg 
of total RNA by Northern blotting analysis. The yield of the circular RNA aptamer in that 
total RNA was estimated to be approximately 24 μg. 
Next, we developed a circular RNA purification method for future inexpensive and 
economical RNA production and purification. We showed that the circular streptavidin 
RNA aptamer was successfully purified with the solid-phase DNA probe technique (Suzuki 
et al., 2002). To purify the circular RNA produced by the PIE method, we designed a 5' 
biotinylated DNA probe that can hybridise with the circular RNA and the circular RNA-
DNA hybrid can be easily trapped using a streptavidin-coated column. The trapped circular 
RNA-DNA hybrid is also denatured with a high concentration of urea (7 M) solution and 
the circular RNA is eluted. We can also choose the elution buffer such that the DNA probe 
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still binds to the solid-phase and it can be reused for another round of RNA purification 
(data not shown). Using a streptavidin-coated column (GE Healthcare), the circular 
streptavidin RNA aptamer was eluted under denaturing conditions and yielded 21 μg of the 
circular RNA (about 88% recovery) from 1 L of E. coli cell culture. Electrophoretic mobility 
shift assay (EMSA) also showed that the purified circular streptavidin RNA aptamer from 
JM109(DE3) retained its binding properties toward streptavidin. 
To verify the suitability of the circular RNA for future RNA therapeutic uses, we 
measured the half-life of the purified circular RNA aptamer in HeLa cell extracts as a 
model of intracellular conditions. The estimated half-life of the purified circular 
streptavidin RNA aptamer was at least 1,386 min, while that of the S1 aptamer, which is 
the linear form of the streptavidin RNA aptamer, was 43 min. These observations 
suggested that the circular RNA escapes exoribonuclease-dependent RNA degradation 
under intracellular conditions. However, the circular RNA degraded completely within 15 
s in 25% human serum. This is reasonable because human serum contains the RNaseA 
family ribonucleases (Haupenthal et al., 2006; Haupenthal et al., 2007; Turner et al., 2007). 
These findings indicated that the circular RNA would be useful under cellular conditions 
only when delivered into the cell in a precise manner, e.g., by using cationic liposomes 
(Sioud & Sorensen, 2003; Sorensen et al., 2003) or virus vector systems (Mi et al., 2006), to 
prevent RNaseA family ribonuclease-dependent degradation. 
2.2 Constitutive in vivo circular streptavidin RNA aptamer expression by the PIE 
method 
We then considered the constitutive circular RNA expression, as the previous expression 
procedure requires monitoring of the optical density for optimal IPTG induction (see 2.1). 
For constitutive expression of the RNA sequence in E. coli, we followed the procedure of 
Ponchon & Dardel (2004). They reported that the M3 vector containing the strong 
constitutively active lipoprotein (lpp) promoter, which is one of the strongest promoters in E. 
coli (Movva et al., 1978; Inoue et al., 1985), is applicable for in vivo RNA expression in the E. 
coli strain JM101Tr (Δ(lac pro), supE, thi, recA56, srl-300.:Tn10, (F', traD36, proAB, lacIq, lacZ, 
ΔM15)). In addition, total RNA expression in JM101Tr is higher than that of JM109(DE3) 
(our unpublished observation).  
Before constructing the constitutive PIE expression plasmid, we replaced the original 
tRNAMet sequence between the lpp promoter and rrnC terminator sequence in the M3 vector 
with the PIE sequence from pGEM-3E5T7t. The resulting expression vector is designated as 
pM3-3E5. The PIE sequence was amplified from the PIE sequence in pGEM-3E5. After 
transformation of pM3-3E5 into the JM101Tr strain, cell density (OD600) was measured at 
several time points during cultivation and 1-mL aliquots were collected from 200 mL of 
2×YT medium. Total RNA was recovered by ISOGEN (Nippon Gene) and Northern blotting 
analysis was performed. At various time points in culture from early logarithmic phase to 
stationary phase, circular RNA was visible in each lane on electrophoretic analysis even 
with ethidium bromide staining. The presence of circular RNA, but not the nicked form, was 
clearly detected on Northern blotting analysis and the amount of circular RNA increased 
with cell growth. These results suggested that the lpp promoter was active and drove 
expression of the PIE sequence without any induction. The stain JM101Tr is positive for 
ribonucleases, such as ribonuclease II (Frazão et al., 2006). Therefore, these observations 
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indicated that the circular RNA also accumulated in the E. coli JM101Tr strain, escaping 
degradation by exonucleases as seen in the previous expression system described in Section 
2.1. The resulting yield of circular RNA after 18 h of cultivation at 30°C was estimated to be 
3.6 ± 0.15 ng per 1 μg of total RNA, which was approximately 1.5-fold higher than that of the 
previous method (Umekage & Kikuchi, 2009a) (see 2.1). These observations indicated 
effective constitutive circular RNA expression in this system.  
2.3 Improving circular RNA expression with the tandem one-way transcription of PIE 
(TOP) technique 
To augment the circular RNA expression in E. coli, we developed the TOP (tandem one-way 
transcription of PIE) technique, which is a simple methodology for increasing the copy 
number of the PIE sequence in a single plasmid. The TOP technique is shown schematically 
in Fig. 3A. With this technique, it is easy to amplify the copy number by sequential insertion 
of the transcriptional unit in a single plasmid (Fig. 3B). First, we amplified the 
transcriptional unit, which consists of the lpp promoter, PIE sequence and rrnC terminator in 
pM3-3E5 (see Section 2.1) with both the 5' flanking sequence containing KpnI–XhoI sites and 
the 3' flanking sequence containing a SalI site. Next, we digested the amplified sequence 
with KpnI and SalI, and the resulting fragment was inserted into the M3 plasmid double-
digested with KpnI and XhoI. The digested XhoI site on the M3 plasmid and the SalI site on 
the amplified fragment can hybridise with mutual 3' protruding ends of the palindromic 
TCGA sequence, and the resulting ligated fragment forms the sequence GTCGAG, which 
can be digested with neither XhoI nor SalI (Fig. 3B). Therefore, the inserted sequence is as 
follows: 5'-KpnI-XhoI-lpp promoter-PIE sequence-rrnC terminator sequence-GTCGAG site-3' 
(Fig. 3C). Thus, the subsequent transcriptional unit can be inserted at the KpnI–XhoI site. We 
constructed four series of pTOP vectors using M3 designated as pTOP(I), pTOP(II), 
pTOP(III) and pTOP(IV) in parallel with the number of inserted transcriptional units. 
This pTOP plasmid has a constitutive lpp promoter and therefore the constitutive expression 
of the PIE sequence in JM101Tr is expected, similar to that using the constitutive expression 
plasmid pM3-3E5 described in Section 2.2. To demonstrate the availability of the TOP 
technique, we then analysed the circular streptavidin RNA aptamer expression in E. coli by 
Northern blotting analysis and we detected that the circular RNA expression was expressed 
in all pTOP vectors (pTOP(I), (II), (III) and (IV) ) (Fig. 3D). 
As shown in the Fig. 3D., the circular RNA expression increased until two tandem insertions 
of the PIE, and the expression yields were almost the same using pTOP(II) and pTOP(III) 
(Table 2). These results indicated that the TOP system is a potentially useful and simple 
methodology for increasing circular RNA expression in E. coli. The circular RNA expression 
using pTOP(II) was estimated to be about 9.7 ± 1.0 ng per 1 μg of total RNA after 18 h of 
cultivation and this yield was approximately 2.7-fold higher than that of the expression 
procedure using the pM3-3E5 system as described in Section 2.2. In addition, the circular 
RNA expression in 1 L of culture medium was estimated to be approximately 0.19 mg, 
which is the highest yield of circular RNA expression in E. coli reported to date. In contrast, 
expression of the circular RNA dropped dramatically when using pTOP(IV); the reason for 
this drop in expression level is not yet clear. To address this problem, we collected pTOP(IV) 
after 18 h of cultivation in JM101Tr and the plasmid was single-digested with HindIII and 








Fig. 3. Construction of the pTOP vectors, and the availability of the TOP method for 
generating circular RNA in JM101Tr. (A) Outline of the TOP method. (B) Illustration of 
sequential insertion of the PIE sequence into the same plasmid. First, KpnI and XhoI double 
digested plasmid and KpnI and SalI double digested insertion sequence were prepared. Both 
the KpnI site from the plasmid and the insertion sequence are ligated and the XhoI-digested 
site in the plasmid and the SalI-digested site in the insertion sequence are ligated, resulting 
in the sequence GTCGAG at the 3' side of the inserted site. (C) Nucleotide sequence of one 
unit of the TOP system. Arrows represent splicing positions of this PIE sequence: yellow, the 
PIE sequence; blue box, lpp promoter sequence; italicised sequence in the blue box, –35 and –
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10 regions of the lpp promoter; red upper case letters, aptamer sequence and rrnC terminator 
sequence; lower case letters in the yellow region, intron sequence of the td gene; bold lower 
case letters, exon sequence of the td gene; bold, circularised sequence; boxed sequence, 
ligated sites. (D) Northern blotting analysis of the circular RNA expression by each pTOP 
series. Total RNA derived from JM101Tr containing the in vivo expressed circular 
streptavidin RNA aptamer was fractionated by 10% denaturing PAGE. In addition, the 
circular RNA expression monitored using the 32P-labelled complementary oligo-DNA probe 
of the aptamer sequence (5'-CCAATATTAAACGGTAGACCCAAGAAAACATC-3'). 5S 
rRNA was monitored as an internal control using the 32P-labelled complementary oligo-
DNA probe sequence (5'- GCGCTACGGCGTTCACTTC-3'). Arrows indicate the migration 
positions of the circular RNA (circular), nicked RNA (nicked) and 5S rRNA. Circular RNA 
control marker (M) was prepared by in vitro transcription (Umekage & Kikuchi, 2009a). “-”, 
Total RNA from JM101Tr; “M3”, negative control of the TOP system lacking the PIE 
sequence. Roman numerals I, II, III and IV represent the total RNA from JM101Tr 
harbouring pTOP(I), pTOP(II), pTOP(III) and pTOP(IV), respectively. 
showed unexpected migration behaviour (data not shown), suggesting that it was difficult 
for pTOP(IV) to undergo replication in JM101Tr during 18 h of cultivation. Although the 
expressional host strain JM101tr has the recA56 mutant, which results in defects in 
recombination, this genetic mutation is not sufficient to confer stability on pTOP(IV). This 
instability of pTOP(IV) in JM101Tr indicates the necessity for optimisation of the TOP 
technique for further augmentation of circular RNA expression; e.g., optimisation of the 
intervening sequence between the two transcriptional units, considering the direction of 
transcription, changing the expressional host to a strain lacking another gene that results in 
defective recombination, such as sbcB, C or another rec gene (Palmer et al., 1995), and 
optimising the copy number of PIE sequences in the single transcriptional unit to avoid 
accumulation of lpp promoter in the single plasmid. 
2.4 Circular RNA expression by the marine phototrophic bacterium Rhodovulum 
sulfidophilum 
Finally, we would like to discuss our new project to develop an economical and efficient 
method for RNA production using the marine phototrophic bacterium Rdv. sulfidophilum 
(Fig. 4), taking advantage of its unique characteristics in that nucleic acids are produced 
extracellularly (Suzuki et al., 2010). In addition this bacterium produces no RNases in the 
culture medium (Suzuki et al., 2010). Although the mechanism of extracellular RNA 
production by this bacterium has not been fully characterised, this extracellular RNA 
expression system represents an economical and efficient methodology for RNA production 
as it is only necessary to collect the culture medium containing extracellularly produced 
RNA and purify the RNA of interest with a column bypassing the need for a cell extraction 
procedure using phenol or various other extraction reagents to rupture the cell membrane. 
We began by constructing the engineered circular RNA expression plasmid, pRCSA, based 
on the broad-host range plasmid pCF1010 (Lee & Kaplan, 1995). The PIE sequence was 
amplified from pGEM-3E5T7t, and the rrnA promoter and puf terminator sequence were 
amplified from the genomic DNA of Rdv. sulfidophilum DSM 1374T (Hansen & Veldkamp, 
1973; Hiraishi & Ueda, 1994). The resulting amplified DNA fragments were inserted into 
pCF1010 to give pRCSA, which was then transformed into Rdv. sulfidophilum DSM 1374T by 
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conjugation using the mobilising E. coli strain S-17 as a plasmid donor (Simon et al., 1983). 
The heat shock transformation method can also be used (unpublished observation) (Fornari 
& Kaplan, 1982). The transformed Rdv. sulfidophilum DSM 1374T was cultured under 
anaerobic conditions under incandescent illumination (about 5,000 lx) for 12 – 16 h at 25°C 
in PYS-M medium (Nagashima et al., 1997, Suzuki et al., 2010). Cultured cells were harvested 
and the total intracellular RNA was extracted with the AGPC method. The estimated yield 
of the intracellular circular RNA was approximately 1.3 ng per 1 L of culture medium by 
Northern blotting analysis. On the other hand, the circular RNA expression in the culture 
medium was barely detected by Northern blotting analysis; however, RT-PCR analysis 
demonstrated the existence of circular RNA in the cultured medium (data not shown). At 
present, neither intracellular nor extracellular expression of the circular RNA aptamer can 
be achieved at practical levels for economic and efficient circular RNA expression, and the 
overall improvement of RNA expression using this bacterium is strongly promoted. 
 
Fig. 4. Overview for circular RNA expression using Rdv. sulfidophilum DSM 1374T. Circular 
RNA expression plasmid, pRCSA, was transformed into Rdv. sulfidophilum DSM 1374T by 
conjugation using the mobilising E. coli strain S-17 (Simon et al., 1983) or by direct 
transformation using the heat shock method (Fornari & Kaplan, 1982). The transformed Rdv. 
sulfidophilum was grown under anaerobic-light conditions. The PIE sequence in pRCSA was 
transcribed with the endogenous RNA polymerase and circular RNA was generated from 
the PIE sequence. The circular RNA produced inside the cell was released extracellularly 
into the culture medium. 
3. Conclusions 
Our circular streptavidin RNA aptamer expression system described in Sections 2.1, 2.2 and 
2.3 is summarised in Table 2. To our knowledge, the TOP method is the most effective 
means of circular RNA expression, and the in vivo constitutive RNA expression is suitable 
for circular RNA expression, as the spontaneously expressed circular RNA can exist stably 
within the cell avoiding endogenous exoribonuclease-dependent degradation. By using the 
circular streptavidin RNA aptamer expression plasmid pTOP(II) and E. coli JM101Tr as a 
host stain, the expression yield of the circular RNA was estimated to be approximately 0.19 
mg per 1 L of culture. Although the TOP method requires further improvement to augment 
circular RNA expression, it is notable that this method easily increased the level of circular 
RNA expression by simple multiplying the copy number of transcription units in the single 
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plasmid. Therefore, we assumed that the TOP strategy will be more effective especially 
using a low copy number plasmid, because increasing the plasmid copy number by genetic 
engineering is not easy. We also presented the solid-phase DNA probe method as a simple 
purification procedure for in vivo expressed circular RNA, because this technique does not 
require electrophoresis for purifying the circular RNA (Umekage & Kikuchi, 2009a). 
The most remarkable advantage of circularising functional RNAs is protection from 
exoribonuclease-induced degradation without the need for chemical modifications, such as 
use of 2'-protected nucleotides (e.g., 2'-fluoro, 2'-O-methyl, LNA) (Schmidt et al., 2004; 
Burmeister et al., 2005; Di Primo et al., 2007; Pieken et al., 1991) or phosphorothioate linkages 
(Kang et al., 2007). Although chemical synthesis of RNA molecules is currently the main 
methodology used for synthetic RNA production, the in vivo circular RNA production 
technique described in this chapter is a promising method for future RNA drug production 
because it is both economical and the product can be purified simply. In addition, circular 
RNA without any chemical modification would be safer than chemically modified RNA for 
therapeutic human use. 
This PIE method can be applied in any species because it requires only magnesium ions and 
guanosine nucleotides. However, the expression of circular RNA inside human cells or other 
mammalian cells in culture has not been examined. Therefore, we are currently examining 
circular RNA expression in human cells based on this method for future development of 
gene therapy methodologies. We assume that PIE transcription and concomitant RNA 
circularisation take place in the nucleus, and therefore the circular functional RNA 
(including aptamers, ribozymes, dsRNA etc.) expression within the nucleus will represent a 
novel gene regulation method targeting nuclear events, such as transcription (Battaglia et al., 
2010), RNA splicing (van Alphen et al., 2009), telomere repairing (Folini et al., 2009) and 
chromatin modification (Tsai et al., 2011). 
Plasmid Host strain Expression 
Yield 
(ng/μg) Reference 
pGEM-3E5T7t JM109(DE3) IPTG 2.5 ± 0.46 Umekage & Kikuchi, 2009a 
pM3-3E5 JM101Tr constitutive 3.6 ± 0.15 Umekage & Kikuchi, 2009b 
pTOP(I) JM101Tr constitutive 5.0 ± 1.5 this study 
pTOP(II) JM101Tr constitutive 9.7 ± 1.0 this study 
pTOP(III) JM101Tr constitutive 9.0 ± 1.8 this study 
pTOP(IV) JM101Tr constitutive 1.8 ± 0.70 this study 
Table 2. Summary of circular RNA expression. “IPTG” and “constitutive” indicate that the 
circular RNA expression was induced by the addition of IPTG and constitutive expression 
of the circular RNA by the constitutive lpp promoter, respectively. “Yield” represents the 
circular RNA expression yield (ng) per 1 μg of total RNA recovered from the harvested cells. 
The data include standard deviations (±), which were derived from three independent 
experiments (n = 3). 
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